Role of urinary podocalyxin in early diagnosis of diabetic nephropathy

1. UMANATH K., LEWIS JB., Update on Diabetic Nephropathy: Core Curriculum 2018, Am. J. Kidney. Dis., 2018, 71(6):884–895.Search in Google Scholar

2. PUGLIESE G., PENNO G., NATALI A., BARUTTA F., DI PAOLO S., REBOLDI G. et al., Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”, J. Nephrol., 2020, 33(1):9–35.Search in Google Scholar

3. PERSSON F., ROSSING P., Diagnosis of diabetic kidney disease: state of the art and future perspective, Kidney. Int. Suppl (2011), 2018, 8(1):2–7.Search in Google Scholar

4. UWAEZUOKE SN., The role of novel biomarkers in predicting diabetic nephropathy: a review, Int. J. Nephrol. Renovasc. Dis., 2017, 10:221–231.10.2147/IJNRD.S143186556636728860837Search in Google Scholar

5. LEE SY., CHOI ME., Urinary biomarkers for early diabetic nephropathy: beyond albuminuria, Pediatr. Nephrol., 2015, 30(7):1063–1075.Search in Google Scholar

6. DAI H., LIU Q., LIU B., Research Progress on Mechanism of Podocyte Depletion in Diabetic Nephropathy., J. Diabetes. Res., 2017, 2017:2615286.10.1155/2017/2615286553429428791309Search in Google Scholar

7. LIAPIS H., ROMAGNANI P., ANDERS HJ., New insights into the pathology of podocyte loss: mitotic catastrophe., Am. J. Pathol. 2013, 183(5):1364–1374.Search in Google Scholar

8. MATOVINOVIC MS., 3. Podocyte Injury in Glomerular Diseases., EJIFCC, 2009, 20(1):21–27.Search in Google Scholar

9. NAKAMURA T., USHIYAMA C., SUZUKI S., HARA M., SHIMADA N.,EBIHARA I. et al., Urinary excretion of podocytes in patients with diabetic nephropathy, Nephrol. Dial. Transplant., 2000, 15:1379–1383.10.1093/ndt/15.9.137910978394Search in Google Scholar

10. WEIL EJ., LEMLEY KV., MASON CC., YEE B., JONES LI., BLOUCH K. et al., Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy, Kidney. Int., 2012, 82(9):1010–1017.Search in Google Scholar

11. FISHEA T., Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients, Biomark. Res., 2015, 3:16.10.1186/s40364-015-0042-3449123926146561Search in Google Scholar

12. NAUTA FL., BOERTIEN WE., BAKKER SJL., GOOR HV., OEVEREN WV., YONG PE. et al., Glomerular and tubular damage markers are elevated in patients with diabetes, Diabetes. Care., 2011, 34:975–981.10.2337/dc10-1545306406021307379Search in Google Scholar

13. KANDASAMY Y., SMITH R., LUMBERS ER., RUDD D., Nephrin – a biomarker of early glomerular injury, Biomark. Res., 2014, 2:21.10.1186/2050-7771-2-21436319225789166Search in Google Scholar

14. SEKULIC M., SEKULIC PS., A compendium of urinary biomarkers indicative of glomerular podocytopathy, Pathol. Res. Int., 2013, 2013:782395.10.1155/2013/782395384533624327929Search in Google Scholar

15. GLUHOVSCHI C., GLUHOVSCHI G., PETRICA L., TIMAR R., VELCIOV S., IONITA I. et al., Urinary Biomarkers in the Assessment of Early Diabetic Nephropathy, J. Diabetes. Res., 2016, 2016:4626125.10.1155/2016/4626125492799027413755Search in Google Scholar

16. REISER J., ALTINTAS MM., Podocytes, F1000Res, 2016, 5:F1000 Faculty Rev-114.10.12688/f1000research.7255.1475540126918173Search in Google Scholar

17. NIELSEN J., MCNAGNY K., The Role of Podocalyxin in Health and Disease, J. Am. Soc. Nephrol., 2009, 20(8):1669–1676.Search in Google Scholar

18. KOSTOVSKA I., TRAJKOVSKA TK., CEKOVSKA S., SPASOVSKI G., LABUDOVIC D., Nephrin and Podocalyxin – New Podocyte Proteins for Early Detection of Secondary Nephropathies, BANTAO J., 2016, 14(1):11–16.Search in Google Scholar

19. SUN D., ZHAO X., MENG L., Relationship between urinary podocytes and kidney diseases, Ren. Fail. 2012, 34(3):403–407.10.3109/0886022X.2011.64962722250862Search in Google Scholar

20. AGARWAL R., Diabetic nephropathy, proteinuria, and progression of CKD, Clin. J. Am. Soc. Nephrol., 2009, 4:1523–1528.10.2215/CJN.0201030919478099Search in Google Scholar

21. KDIGO., Chapter 1: Definition and classification of CKD, Kidney. Int. Suppl., 2013, 3:19.10.1038/kisup.2012.64408969325018975Search in Google Scholar

22. COCKROFT DW., GAULT MH., Prediction of creatinine clearance from serum creatinine, Nephron., 1976, 16:31–41.10.1159/0001805801244564Search in Google Scholar

23. NAVRA AS., BILOUS RW., Laboratory Assessment of Diabetic Kidney Disease, Diabetes. Spectr., 2015, 28(3):162–166.Search in Google Scholar

24. ŠIMUNDIC AM., Measures of Diagnostic Accuracy: Basic Definitions, EJIFCC., 2009, 19(4):203–211.Search in Google Scholar

25. HABIBZADEH F., HABIBZADEH P., YADOLLAHIE M., On determining the most appropriate test cut-off value: the case of tests with continuous results, Biochem. Med., 2016, 26(3):297–307.Search in Google Scholar

26. CHIDA S., FUJITA Y., OGAWA A., HAYASHI A., ICHIKAWA R., HAYASHI A. et al., Levels of albuminuria and risk of developing macroalbuminuria in type 2 diabetes: historical cohort study, Sci. Rep., 2016, 6:26380.10.1038/srep26380487647527210499Search in Google Scholar

27. El-SAEED GK., SHEHAB El-DEEN WA., MONTASR BA., OMAR TA., MOHAMED DS., Urinary podocalyxin and cyclophilin A: markers for early detection of type 2 diabetic nephropathy, Menoufia. Med. J., 2019, 32:996–1003.10.4103/mmj.mmj_223_18Search in Google Scholar

28. Al-RUBEAAN K., SIDDIQUI K., Al-GHONAIM MA., YOUSSEF AM., Al-SHARQAWI AH., AlNAQEB D., Assessment of the diagnostic value of different biomarkers in relation to various stages of diabetic nephropathy in type 2 diabetic patients, Sci. Rep., 2017, 7(1):2684.Search in Google Scholar

29. YE H., BAI X., GAO H., LI L., WU C., SUN X. et al., Urinary podocalyxin positive-element occurs in the early stage of diabetic nephropathy and is correlated with a clinical diagnosis of diabetic nephropathy, J. Diabetes. Complicat., 2014, 28:96–100.10.1016/j.jdiacomp.2013.08.00624075693Search in Google Scholar

30. HARA M., YAMAGATA K., TOMINO Y., SAITO A., HIRAYAMA Y., OGASAWARA S. et al., Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin, Diabetologia., 2012, 55(11):2913–2919.10.1007/s00125-012-2661-7346437122854890Search in Google Scholar

31. SHOJI M., KOBAYASHI K., TAKEMOTO M., SATO Y., YOKOTE K., Urinary podocalyxin levels were associated with urinary albumin levels among patients with diabete, Biomarkers., 2016, 21(2):164–167.Search in Google Scholar

32. WANG R.,YAO C., LIU F., Association between Renal Podocalyxin Expression and Renal Dysfunction in Patients with Diabetic Nephropathy: A Single-Center, Retrospective Case-Control Study, BioMed. Res. Int., 2020, Article ID 7350781.10.1155/2020/7350781715779032337271Search in Google Scholar

33. BACCI MR., CHEHTER EZ., AZZALIS LA, COSTA DE AGUIAR ALVES B., FONCESKA FLA., Serum NGAL and Cystatin C Comparison With Urinary Albumin-to-Creatinine Ratio and Inflammatory Biomarkers as Early Predictors of Renal Dysfunction in Patients With Type 2 Diabetes, Kidney. Int. Rep., 2016, 2(2):152–158.Search in Google Scholar